Tekla Life Sciences Investors (HQL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tekla Life Sciences Investors (HQL) has a cash flow conversion efficiency ratio of -0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.28 Million) by net assets ($513.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tekla Life Sciences Investors net asset quality index to measure how much of total assets are equity-financed.
Tekla Life Sciences Investors - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Tekla Life Sciences Investors's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HQL operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Tekla Life Sciences Investors Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tekla Life Sciences Investors ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Queen's Road Capital Investment Ltd.
TO:QRC
|
0.006x |
|
Laurent-Perrier
PA:LPE
|
0.002x |
|
Wuxi Xuelang Environmental Technology Co Ltd
SHE:300385
|
0.201x |
|
XiAn Catering Co Ltd
SHE:000721
|
-0.258x |
|
MapLight Therapeutics, Inc. Common Stock
NASDAQ:MPLT
|
-0.102x |
|
LS Materials
KQ:417200
|
0.016x |
|
Hichain Logistics Co Ltd
SHE:300873
|
0.031x |
|
Dexus Industria REIT
AU:DXI
|
0.022x |
Annual Cash Flow Conversion Efficiency for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual cash flow conversion efficiency of Tekla Life Sciences Investors from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Tekla Life Sciences Investors (HQL) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $513.66 Million | $-2.32 Million | -0.005x | -319524554.28% |
| 2021-09-30 | $523.44 Million | $-0.74 | 0.000x | +12.40% |
| 2019-09-30 | $384.16 Million | $-0.62 | 0.000x | +100.00% |
| 2014-09-30 | $444.09 Million | $-52.57K | 0.000x | -477.75% |
| 2013-09-30 | $302.29 Million | $9.47K | 0.000x | -99.97% |
| 2012-09-30 | $227.08 Million | $21.11 Million | 0.093x | -86.60% |
| 2011-09-30 | $170.60 Million | $118.30 Million | 0.693x | +9075.24% |
| 2010-09-30 | $251.40 Million | $1.90 Million | 0.008x | -85.55% |
| 2009-09-30 | $248.60 Million | $13.00 Million | 0.052x | +23.11% |
| 2008-09-30 | $277.80 Million | $11.80 Million | 0.042x | +453.59% |
| 2007-09-30 | $308.00 Million | $-3.70 Million | -0.012x | -53.37% |
| 2006-09-30 | $268.10 Million | $-2.10 Million | -0.008x | +43.87% |
| 2005-09-30 | $229.30 Million | $-3.20 Million | -0.014x | +16.35% |
| 2004-09-30 | $191.80 Million | $-3.20 Million | -0.017x | -32.36% |
| 2003-09-30 | $190.40 Million | $-2.40 Million | -0.013x | +23.59% |
| 2002-09-30 | $157.60 Million | $-2.60 Million | -0.016x | -86.77% |
| 2001-09-30 | $215.10 Million | $-1.90 Million | -0.009x | +48.04% |
| 1998-09-30 | $100.00 Million | $-1.70 Million | -0.017x | -49.60% |
| 1997-09-30 | $132.00 Million | $-1.50 Million | -0.011x | +6.74% |
| 1996-09-30 | $123.10 Million | $-1.50 Million | -0.012x | -- |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more